Introduction Per-oral endoscopic myotomy (POEM) is a novel technique which involves performing a myotomy endoscopically after creating a submucosal tunnel. Despite being widely adopted in the USA, Europe and Asia, its introduction into the UK has been limited. We describe one of the first series of POEM procedures in the UK, assessing its feasibility, safety and efficacy. Method POEM was performed as inpatient under general anaesthesia with endotracheal intubation using the Olympus video endoscopy system. Two experienced endoscopists performed the procedures after undergoing hands on training in live animal models. The procedure involved mucosal entry, submucosal tunnelling, myotomy and clip closure of mucosal defect. The Endolumenal Functional Lumen Imaging Probe (EndoFLIP) was used to assess the gastroesophageal junction (GOJ) distensibility at balloon volumes of 30 and 40 ml at the start and end of procedures. Contrast swallow was performed 24-48 hours prior to discharge. Eckardt scores were prospectively recorded at the time initial clinic visit and at follow up visits, 4-8 weeks post procedure. Results Twenty six patients underwent POEM at our institution. Median age was 51 years (interquartile range (IQR) 42-60) and 69% were males. 17 patients (65%) had type II achalasia; 5 (19%) were type I; 2 (8%) type III; and 2 (8%) unclassified. Procedure failed in 2 patients who were excluded from the analysis. Median length of hospital stay was 3 days (IQR 2-3) days. Median (IQR) GOJ pressures reduced from 18.2 (15.3-27.9) and 33.0 (28.2-40.5) to 14.2 (12.4-18) and 23.1 (18-26. 3) mmHg at 30 ml (p=0.10) and 40 ml (p=0.002) volumes, respectively. Median (IQR) Eckardt score was 8 (6-9) pre-procedure and 1 (1-2) post procedure (p<0.001). Perioperative complications included pneumoperitoneum (n=1) and mucosal laceration (n=3) Introduction Coeliac disease (CD) is common yet underdiagnosed. 12.4% CD patients had a gastroscopy within 5 years without duodenal biopsies taken, and coeliac serology was performed in only 30% of patients with anaemia or suspected CD. A pre-endoscopy point of care test (POCT) could potentially fill this gap. We aimed to evaluate the diagnostic accuracy and acceptability of the POCT, Simtomax (IgA/IgG-deamidated gliadin peptide, Tillotts Pharma, Rheinfelden, Switzerland), in detecting CD. Method Group 1: Patients attending for a gastroscopy were prospectively recruited from 2013-17. We excluded patients with a high pre-test probability of CD: positive endomysial antibody (EMA) referrals, previous villous atrophy, self-reported gluten sensitivity, those on a gluten free diet (GFD), suspected gluten ataxia; and known CD. Group 2: Patients who self-reported gluten sensitivity were prospectively recruited. All patients underwent the POCT, tissue transglutaminase antibodies (TTG), EMA and duodenal biopsies. The sensitivities of the POCT were compared to TTG and EMA, measuring against histology as the reference standard. Questionnaires regarding patient preference to the modality of antibody testing were given out. Results Group 1: 1000 patients were recruited (585 females, 58.5%; age range 16-91, median age 57). Forty-one patients (4.1%) were diagnosed with CD.
Group 1:
Abstract OC-040 Table 1 Sensitivity ( Group 2: Seventy patients who self-reported gluten sensitivity were recruited (51 females, 82.9%; age range 17-73, median age 35). Nine patients on a self-imposed GFD were excluded. Of the remaining 61 patients, 42 (68.9%) were diagnosed with non-coeliac gluten sensitivity (NCGS), 17 (27.9%) with CD and 2 (3.3%) with potential CD.
Group 2:
Abstract OC-040 Table 2 Sensitivity ( Five hundred patients responded to the POCT acceptability questionnaire. 90.8% preferred a POCT, 2.8% preferred venepuncture, and 6.8% had no preference. Conclusion The POCT had comparable diagnostic performance to conventional serology. It also correctly identified all cases of CD in a gluten sensitive cohort. The POCT could serve as a valuable and convenient case finding tool, with the advantage of providing antibody results rapidly at the point of endoscopy to target duodenal biopsy sampling for those with a positive POCT. Disclosure of Interest M. Lau: None Declared, P. Mooney: None Declared, W. White: None Declared, M. Rees: None Declared, M. Burden: None Declared, S. Wong: None Declared, M. Kurien: None Declared, D. Sanders Conflict with: Professor Sanders has received educational research grants from Dr Schaer (a gluten-free food manufacturer) and Tillotts Pharma (producer of a point of care test for celiac disease) for investigator led studies. Dr Shaer and Tillott's Pharma did not have any input in the study design, access to study data, interpretation of the findings or drafting of the manuscript.
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MANAGEMENT OF ADULT EOSINOPHILIC OESOPHAGITIS: ANALYSIS OF MEDICAL AND DIETARY OUTCOMES IN A UK CENTRE
1,2 H Hunter*, Introduction Management of eosinophilic oesophagitis (EoE) includes proton pump inhibitors (PPIs), topical steroids, or dietary intervention. In adults dietary management commonly consists of either the six-food elimination diet (SFED) or allergy-test directed food exclusion. To date patient characteristics and outcomes from various interventions have not been reported in a UK population. Method A retrospective evaluation of adults (!16 years) with oesophageal eosinophilia (!15 eos/hpf) over a two-year period was undertaken. Patients were identified from histology reports and clinical records. Treatment episodes were analysed in those who had both pre-and post-intervention biopsies. Patients who underwent dietary interventions were advised by a specialist dietitian.
Results Our search identified 100 subjects 18-84 years of age (median 35) with a predominance of males (76%; 76/100) and Caucasians (94%; 67/71). Atopic conditions were reported in 75% (65/87) and allergy testing with skin prick or specific IgE tests was positive to food allergens for 71% (44/62) and aeroallergens 72% (38/53). PPIs were given first-line for 75% (38/51) and overall 22% fully responded to a PPI (5/23). Fifty-one patients had both biopsies covering 73 treatment episodes (table  1) . Signficant reductions in eosinophil counts were seen for SFED and allergy-test directed diets. There were no significant differences in efficacy between treatment groups.
Abstract OC-041 Table 1 Median peak eosinophil count Through food reintroduction and biopsies 14 patients identified dietary triggers: 57% milk (n=8), 29% gluten containing cereals (n=4), 14% egg (n=2), 7% soya, nuts, shellfish or fruit (each n=1). For those who completed the process (n=10), 50% had only one trigger, 30% two, and 20% three or more. Conclusion Baseline characteristics were comparable to other described cohorts with a high proportion of males, Caucasians and a high rate of atopy. Dietary intervention particularly with the SFED appears to be effective in our population, with a nonsignificant trend to higher response rates compared to other interventions. Since the most common triggers were dairy and cereals, empirical exclusion of these two food groups may be an effective approach. Introduction Oesophageal carcinoma (OC) is the sixth leading cause of cancer-related mortality in the world. Experimental 1 and clinical 2 evidence have shown that statins could potentially play a role in reducing OC incidence. This effect has been studied in new observational data.This is a meta-analysis examining available evidence to assess the impact of statin use on the incidence of OC. Method A systematic literature search of Medline, Embase was used to identify studies that were pertinent to the research objective. Included studies were assigned into one of three subgroup analyses examining incidence of: adenocarcinoma (OAC) in Barrett's oesophagus (BO) cohort, OAC in population cohorts and all types of OC in population cohorts.
